Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia

Rita Nyilas, Laura C. Gregg, Ken Mackie, Masahiko Watanabe, Andreas Zimmer, Andrea G. Hohmann and István Katona

1Institute of Experimental Medicine, Hungarian Academy of Sciences, Szigony u. 43., H-1083 Budapest, Hungary
2Neuroscience and Behavior Program, Department of Psychology, University of Georgia, Athens, GA 30602-3013, USA
3Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, USA
4Department of Anatomy, Hokkaido University School of Medicine, Sapporo 060-8638, Japan
5Institute of Molecular Psychiatry, University of Bonn, 53105 Bonn, Germany

Keywords: 2-AG, CB1, DAGL, metabotropic glutamate receptor, rodent spinal cord

Abstract

Cannabinoid administration suppresses pain by acting at spinal, supraspinal and peripheral levels. Intrinsic analgesic pathways also exploit endocannabinoids; however, the underlying neurobiological substrates of endocannabinoid-mediated analgesia have remained largely unknown. Compelling evidence shows that, upon exposure to a painful environmental stressor, an endocannabinoid molecule called 2-arachidonoylglycerol (2-AG) is mobilized in the lumbar spinal cord in temporal correlation with stress-induced antinociception. We therefore characterized the precise molecular architecture of 2-AG signaling and its involvement in nociception in the rodent spinal cord. Nonradioactive in situ hybridization revealed that dorsal horn neurons widely expressed the mRNA of 2-AG, and CB1 cannabinoid receptor, a receptor for 2-AG, in the superficial dorsal horn, at the first site of modulation of the ascending pain pathway. High-resolution electron microscopy uncovered postsynaptic localization of DAGL-α, the synthesizing enzyme of 2-AG. Peroxidase-based immunocytochemistry demonstrated high levels of DAGL-α protein and CB1 cannabinoid receptor, a receptor for 2-AG, in the superficial dorsal horn, at the first site of modulation of the ascending pain pathway. Taken together, these findings suggest a key role for 2-AG-mediated retrograde suppression of nociceptive transmission at the spinal level. The striking positioning of the molecular players of 2-AG synthesis and action at nociceptive excitatory synapses suggests that pharmacological manipulation of spinal 2-AG levels may be an efficacious way to regulate pain sensation.

Introduction

Cannabis sativa has been used to alleviate pain since antiquity. Its analgesic effects is attributed to its bioactive compounds, the cannabinoids, which produce antinociception, both in animal models of acute and persistent pain and in clinical studies (Walker & Hohmann, 2005; Pacher et al., 2006), by activation of types 1 and 2 cannabinoid receptors (CB1 and CB2; Ledent et al., 1999; Zimmer et al., 1999; Racz et al., 2008; for reviews, see Pertwee, 2001; Guindon & Hohmann, 2008).

Cannabinoid receptors are physiologically activated by their endogenous ligands, the endocannabinoids (Piomelli, 2003), 2-arachidonoylglycerol (2-AG; Mechoulam et al., 1995; Sugira et al., 1995), a postulated ligand for both CB1 and CB2 (Sugira et al., 2006), is the predominant candidate endocannabinoid for being a fast synaptic messenger (Katona & Freund, 2008). A basic molecular organization scheme of 2-AG signaling in several brain areas is emerging (Katona et al., 2006; Yoshida et al., 2006; Lafourcade et al., 2007; Uchigashima et al., 2007; Matyas et al., 2008), with postsynaptic positioning of diacylglycerol lipase-α (DGL-α; Katona et al., 2006; Yoshida et al., 2006), the primary biosynthetic enzyme of 2-AG (Bisogno et al., 2003), and presynaptic localization of CB1 (Katona et al., 1999, 2006; Kawamura et al., 2006). Electrophysiological studies also suggest a retrograde action of 2-AG (Melis et al., 2004; Makara et al., 2005; Hashimoto et al., 2007), which has been proposed to function as a synaptic circuit breaker at brain glutamatergic synapses (Katona & Freund, 2008).

Endogenous 2-AG has also been implicated as a major transmitter subserving endocannabinoid-mediated stress-induced analgesia (Hohmann et al., 2005; Suplita et al., 2006). 2-AG, but not anandamide, is mobilized in lumbar spinal cord following exposure to footshock stress (Suplita et al., 2006). Moreover, spinal 2-AG levels correlate highly with stress antinociception (Hohmann & Suplita, 2006; Suplita et al., 2006). Finally, intrathecal (i.t.) administration of an inhibitor of the 2-AG hydrolyzing enzyme, monoacylglycerol lipase, enhances stress...
antinociception in a CB₁-dependent manner (Suplita et al., 2006). Despite the widespread distribution of 2-AG and its critical role in physiological pain regulation, the molecular machinery responsible for its spinal release and its involvement in pain sensation has not been identified. Previous studies have reported that CB₁ receptors are expressed by primary sensory neurons including nociceptors (Hohmann & Herkenham, 1998, 1999; Ahluwalia et al., 2000; Salio et al., 2002; Mitrarrantakul et al., 2006; Agarwal et al., 2007), and CB₁ activation by cannabinoids inhibited C-fiber-mediated facilitation of spinal nociceptive responses (Chapman, 1999; Strangman & Walker, 1999; Drew et al., 2000; Kelly & Chapman, 2001). However, the anatomical source of endogenous CB₁ ligands modulating nociceptive transmission is unknown.

In the present study, we describe the molecular architecture of 2-AG synthesis at primary nociceptive synapses, and sites of 2-AG action in the rodent spinal cord, using specific and highly sensitive antibodies and high-resolution electron microscopy. In further behavioral studies combined with pharmacological manipulation of 2-AG signaling at the spinal level, we demonstrate the functional importance of this circuitry in vivo. These studies provide the first anatomical and functional evidence for the role of retrograde 2-AG signaling in nociception.

Materials and methods
Perfusion and preparation of tissue sections
Experiments were carried out according to institutional guidelines of ethical code and the Hungarian Animal Care and Experimentation (1998. XXVIII. Section 243/1998), which are in accordance with the European Communities Council Directive of November 24, 1986 (86/609/EEC). Adult wild-type (n = 15, 186 ± 131 days old) and CB₁-knockout (Zimmer et al., 1999; n = 3, 67 ± 9 days old) C57BL/6 mice and male Wistar rats (n = 2, 47 and 74 days old) were deeply anaesthetized with a mixture of ketamine–xylazine (25 mg/mL ketamine, 5 mg/mL xylazine and 0.1 w/w% promethazine in H₂O; 1 mL per 100 g, i.p.), then perfused with fixative containing 4% paraformaldehyde (PFA) in 0.1 M PB. After perfusion, the spinal cord was removed from the spinal vertebrae, and transcardially perfused with 0.9% saline for 2 min, followed by 100 or 400 mL (for mice and rats, respectively) of PFA fixative containing 4% paraformaldehyde (PFA) in 0.1 M PB. The spinal cord was then vacuum rinsed in 0.1 M PB for 20 min. After perfusion, the spinal cord was removed from the spinal cord column and post-fixed for 2 h in 4% PFA, then washed in 0.1 M PB. Transverse sections (50 μm thick) of the spinal cord at the cervical and lumbar levels were cut with a Leica VTS-1000 vibratome (Vibratome, St Louis, MO, USA). For sections subjected to in situ hybridization, diethyldicyclocarbonate (DEPC)-treated PB was used and sectioning was performed under RNase-free conditions. All reagents were purchased from Sigma-Aldrich, Merck, Roche (Basel, Switzerland) or Reanal (Budapest, Hungary), unless otherwise stated.

In situ hybridization
All solutions used for in situ hybridization were first treated with 0.1% DEPC and then autoclaved. Incubation of the slices was carried out in a free-floating manner in RNase-free sterile culture wells for all steps. After washing steps in phosphate-buffered saline containing 0.1% Tween-20 (PBST; pH 7.4), hybridization was performed at 60°C overnight in hybridization buffer containing the digoxigenin-labeled riboprobe (2.5 μg/mL) on a shaker in a humid chamber. We prepared digoxigenin-labeled antisense and sense riboprobes against the same region of the mouse DGL-α sequence that was previously used to characterize the regional and cellular expression pattern of DGL-α in the hippocampus (referred to as Probe 2 in Katona et al., 2006). The length and the sequence of primers used for generating Probe 2 from cDNA derived from total C57BL/6 mouse frontal cortex mRNA are listed below the probe; numbering of the nucleotide positions starts from the beginning of the open reading frame: 1169 bp from 1967 to 3135 (forward primer: 5'-TCA TGG AGG GGC TCA ATA AG, reverse primer: 5'-CTA GCG TGC CGA GAT GAC CA). After incubation with either of the riboprobes, spinal cord sections from adult C57BL/6 wild-type mice (four male, 105 ± 23 days old; one female, 235 days old) were washed for 30 min at 60°C in wash solution 1 (containing 50% formamide, 5 × SSC and 1% SDS in DEPC-treated H₂O) and then twice for 45 min at 60°C in wash solution 2 (containing 50% formamide and 2 × SSC in DEPC-treated H₂O) and in 0.05 M Tris-buffered saline containing 0.1% Tween-20 (TBST; pH 7.6), before sections were blocked in TBST containing 10% normal goat serum (TBSTN) for 1 h at room temperature. Next, sections were incubated at 4°C overnight with sheep antidigoxigenin Fab fragment conjugated to alkaline phosphatase (Roche Molecular Diagnostics, Germany) diluted at 1 : 1000 in TBSTN. The next day, after washing steps in TBST, sections were developed with a chromogenic solution containing 5-bromo-4-chloro-3-indolyl-phosphate and Nitro blue tetrazolium chloride (3.5 μL per 10 mL of both). The sections were rinsed in the developing solution in the dark for 6–18 h, then the reaction was stopped using PBST and washed in PB. Sections were mounted in Vectashield (Vector Laboratories, Burlingame, CA, USA) onto glass slides and the coverslips were sealed with nail polish.

Peroxidase-based immunocytochemistry and pre-embedding immunogold labeling for electron microscopic analysis
After extensive washing in 0.1 M PB, spinal cord sections for peroxidase-based immunocytochemistry from adult C57BL/6 wild-type (10 male, 186 ± 131 days old; three female, 55, 75 and 235 days old) and CB₁-knockout (Zimmer et al., 1999; two male, 58 and 71 days old; one female, 76 days old) mice and Wistar rats (two male, 47 and 74 days old) were first incubated for 10 min in 1% H₂O₂ in 0.1 M PB to block endogenous peroxidase activity, then washed in 0.1 M PB. Sections both for peroxidase-based immunocytochemistry and pre-embedding immunogold labeling were incubated in 30% sucrose overnight, followed by freeze-thawing over liquid nitrogen four times. After washing in 0.1 M PB, sections were processed either for immunoperoxidase, pre-embedding immunogold, or pre-embedding immunogold combined with a second immunoperoxidase, or immunoperoxidase followed by pre-embedding immunogold staining. Subsequently, all washing steps and dilutions of the antibodies were done in 0.05 M Tris-buffered saline (TBST; pH 7.4). Following extensive washing in TBST, sections were blocked in 5% normal goat serum for 45 min, then incubated with one of the two polyclonal affinity-purified guinea pig anti-CB₁ (1 : 150–1 : 200 and 1 : 530; ~1 μg/mL) antibodies (Fukudome et al., 2004) or with a polyclonal affinity-purified guinea pig or rabbit anti-DGL-α antibody (1 : 500, 0.76 μg/mL, termed ‘C-42’ in Yoshida et al., 2006; and 1 : 1000–1 : 3000, ~0.3–1 μg/mL, termed ‘INT’ in Katona et al., 2006; respectively) alone or mixed with an affinity-purified guinea pig anti-metabotropic glutamate receptor 5 (mGlur₅) antibody (1 : 300; ~1 μg/mL; Uchigashima et al., 2007) for 48 h at 4°C. To test the specificity of the DGL-α antibody, parallel staining on the neighboring sections from the same spinal cord was carried out with the mix of the DGL-α antibody and its blocking peptide (1 μg/mL) following their preincubation at 4°C overnight. The specificity of the anti-CB₁ antibodies was confirmed by the lack of immunostaining in sections derived from CB₁-knockout mice. In the immunoperoxidase staining.
procedure, after primary antibody incubations and TBS washing steps, sections were treated with biotinylated goat antiguinea pig IgG or with biotinylated goat antirabbit IgG (both 1 : 300–1 : 500; Vector Laboratories) for 2 h and then, after washing with TBS, incubated with avidin-biotinylated horseradish peroxidase complex (1 : 500; Elite-ABC, Vector Laboratories) for 1.5 h. The immunoperoxidase reaction was developed, after washing with TBS and TB, using 3,3′-diaminobenzidine (DAB) as chromogen and 0.01% H2O2 dissolved in TB (pH 7.6). In the immunogold staining procedure, sections were incubated in 0.8 nm gold-conjugated goat antiguinea pig or goat antirabbit antibody for CB1 and mGluR5 or DGLα incubated in 0.8 nm gold-conjugated goat antiguinea pig or goat antirabbit antibody for CB1 and mGluR5 or DGLα, respectively (both 1 : 50; Aurion, the Netherlands), overnight at 4°C. Then sections were silver-intensified using the silver enhancement system R-GENT SE-EM according to the kit protocol (Aurion). In the double immunostaining experiments, sections were either developed first for immunogold and then for immunoperoxidase staining or first for immunoperoxidase and then for immunogold labeling. Lack of crossreactivity of the secondary antibodies in the sequential detection scheme was verified by omission of the primary antibody, which eliminated labeling by the irrelevant secondary antibody. After development of the immunostaining, sections were treated with 0.5–1% OsO4 in 0.1 m PB for 15–20 min, dehydrated in an ascending series of ethanol and acetone, and embedded in Durcupan (ACM, Fluka, Buchs, Switzerland). During dehydration, sections were treated with 1% uranyl acetate in 70% ethanol for 15–20 min. From sections embedded in Durcupan, areas of interest were re-embedded and resected for electron microscopy. Ultrathin sections (60 nm thickness) were collected on Formvar-coated single-slot grids and stained with lead citrate.

**Light- and electron microscopic analysis and image processing**

Tissue sections subjected to in situ hybridization and peroxidase-based immunocytochemistry were analyzed on a ZEISS Axioplan 2 microscope using Plan-NEOFLUAR 5x–63x objectives and were photographed with an Olympus DP70 digital camera. Electron micrographs were taken at 30 000–50 000× magnification with a Hitachi 7100 electron microscope. For the adjustment of digital photographs, Adobe Photoshop CS2 software (Adobe Systems, San Jose, CA, USA) was used. In all imaging processes, adjustments (brightness and contrast) were done in the whole frame and no part of an image was modified separately in any way.

**Ultrastructural criteria for nociceptive axon terminal identification**

For the identification of nociceptive axon terminals in the spinal dorsal horn, we used the following morphological criteria defining synaptic glomeruli described previously (Ribeiro-da-Silva & Coimbra, 1982; Ribeiro-da-Silva, 1995). Type I glomeruli formed by unmyelinated (mainly nociceptive C-) fibers occurring predominantly in dorsal lamina II (LII outer to dorsal LII inner) were identified by bearing a small central terminal of indented contour with dark axoplasm, closely packed clear spherical vesicles of variable size and only very few mitochondria. A subpopulation of these terminals containing more than three dense-core vesicles corresponds to peptidergic unmyelinated fibers. Around the core terminal, dendritic spines, vesicle-containing dendritic spines and axon endings were situated. Type II glomerular terminals of small myelinated primary afferents (Aδ-fibers), prevailed in ventral lamina II (ventral LII inner) and lamina III, were identified as electron-lucent, large boutons with regular contours, and loosely distributed, agranular round synaptic vesicles of uniform diameter, numerous mitochondria and sometimes neurofilaments, surrounded by fewer vesicle-containing dendrites and more axon endings. In apposition to the core bouton of a glomerulus at least four surrounding profiles and two or more synaptic specializations were required to become accepted as a type I or type II glomerulus. To determine whether the terminals fulfilled these criteria they were followed through consecutive serial sections.

**Surgical procedures**

One hundred and fifty-four adult male Sprague-Dawley rats were used in the in vivo experiments. All procedures were approved by the University of Georgia Animal Care and Use Committee and followed the guidelines for the treatment of animals of the International Association for the Study of Pain (Zimmermann, 1983).

Rats were anesthetized using a sodium pentobarbital and ketamine mixture (25 and 40 mg/kg, respectively), administered intraperitoneally. PE10 tubing was used to construct the i.t. catheters (Yakash & Rudy, 1976; Hohmann et al., 1998). Catheters were implanted through an incision in the atlanto-occipital membrane to a depth of 8.5 cm so that the catheter tip was positioned rostral to the lumbar enlargement. Catheters were anchored to the skull with dental acrylic and a stainless steel screw. Animals exhibiting signs of motor dysfunction induced by i.t. catheter placement were discarded and did not receive pharmacological manipulations. Animals were allowed to recover for 5–7 days prior to testing.

**Drug preparation and administration**

(S)-3,5-dihydroxyphenylglycine (DHPG) was obtained from Tocris Cookson (Ellisville, MO, USA). N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A, rimonabant) was a gift from NIDA, N-formyl-L-leucine (1S)-1-[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester [(-)-tetrathydrodipristatin, THL] and 2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP hydrochloride) were obtained from Sigma-Aldrich (St Louis, MO, USA). All drugs were dissolved in a vehicle containing 60% DMSO and 40% saline. Drugs were delivered in a single 10-μl volume and delivered intrathecally (i.t.). Therefore, for all experiments requiring co-administration of multiple agents, all compounds were administered i.t. in a single 10-μl volume of 60% DMSO and 40% saline. Vehicle groups, therefore, always consisted of animals receiving a single 10-μl injection of 60% DMSO and 40% saline. Effects of pharmacological manipulations were always compared to controls employing the same 60% DMSO-containing vehicle tested under identical conditions by a single experimenter, blinded to the drug condition.

**Behavioral testing**

Stress antinociception was quantified behaviorally using the tail-flick test (D’Amour & Smith, 1941), which measures the latency for a rat to remove its tail from a radiant heat source (IITC Inc., Model 33A, Woodland Hills, CA, USA). Rats were habituated to the restraining tubes for 15 min prior to testing. Cutoff latencies (10 or 15 s) were uniformly employed within any given study to prevent tissue damage. The 15-s cutoff latency was employed to facilitate detection of enhancements in stress antinociception induced by pharmacological manipulations. Stable baseline withdrawal responses to thermal
stimulation of the tail were initially established prior to pharmacological manipulations. Intrathecal injections were administered manually using a Hamilton syringe and consisted of 10 μl of drug or vehicle followed by 10 μl of saline to flush the catheter. Immediately following injection, tail-flick latencies were measured three times at 2-min intervals and averaged to assess possible changes in nociceptive thresholds induced by pharmacological manipulations before exposure to footshock stress. Rats were subsequently exposed to continuous footshock for 3 min (0.9 mA, AC) to induce stress antinociception, as described previously (Hohmann et al., 2005; Suplita et al., 2005, 2006, 2008). Tail-flick latencies were measured over 40 min following footshock at 2-min intervals. Every two consecutive measurements were averaged for each rat before (baseline) and after (post-shock) exposure to footshock to create two point blocks that were used for repeated measure statistical analyses, using methods identical to those reported previously (Hohmann et al., 2005; Suplita et al., 2005, 2006, 2008). Group means of these two point averages are depicted graphically in Figs 6 and 7. Intrathecal injections were delivered 5 min prior to exposure to footshock. Catheter placements were verified following completion of testing by injection of fast green dye followed by dissection. Animals exhibiting damage to the spinal cord induced by catheter placement were excluded from data analysis. In all experiments, the experimenter was blinded to the experimental condition.

Role of group I mGluRs in endocannabinoid-mediated stress antinociception

To determine whether activation of group I mGluRs in the spinal cord altered endocannabinoid-mediated stress antinociception, rats received either the group I mGluR agonist DHPG (0.02 or 0.2 μg) or vehicle i.t. prior to exposure to footshock. Separate groups received the group I mGluR antagonist MPEP (2.3 × 10^{-5}, 2.3 × 10^{-4} and 0.23 μg i.t.) or vehicle to determine whether blockade of mGluR5 receptors at the spinal level would suppress stress antinociception. Low doses of DHPG and MPEP were selected to avoid alterations in basal nociceptive thresholds in the tail-flick test (Gabra et al., 2007), which was also confirmed in the present experiments. To determine pharmacological specificity, separate groups received either DHPG (0.2 μg i.t.), DHPG (0.2 μg i.t.) co-administered with MPEP (2.3 × 10^{-5} μg i.t.), or vehicle prior to exposure to the stressor. To determine whether DHPG-induced changes were dependent upon CB1 receptor activation, DHPG (0.2 μg i.t.) was administered alone or co-administered with rimonabant (10 μg i.t.). The dose of rimonabant was selected based upon our previous work showing that i.t. administration of the same dose was insufficient to inhibit stress antinociception (Suplita et al., 2006). Tail-flick latencies were measured before and after exposure to footshock as previously described (Hohmann et al., 2005; Suplita et al., 2006).

Role of DGL in endocannabinoid-mediated stress antinociception

To determine whether pharmacological inhibition of DGL at the spinal level suppressed endocannabinoid-mediated stress antinociception, rats received either THL (10 or 100 μg i.t.), at doses that lacked intrinsic effects on basal nociceptive thresholds in the absence of footshock, or vehicle i.t. Effects of a low dose of THL (1 μg i.t.) on stress antinociception was additionally compared to vehicle using the same cutoff latency (15 s) employed to facilitate detection of enhancements of stress antinociception induced by i.t. DHPG. To evaluate whether activation of group I mGluRs at the spinal level enhanced stress antinociception through a DGL-dependent mechanism, DHPG (0.2 μg i.t.) was administered either alone or with THL (1 μg i.t.). Tail-flick latencies were measured before and after exposure to footshock as previously described (Hohmann et al., 2005).

Statistical analysis

Behavioral data were analyzed by repeated-measures ANOVA and ANOVA using methods identical to those employed in our previously published work (Hohmann et al., 2005; Suplita et al., 2005, 2006, 2008), SPSS (version 16.0; SPSS Incorporated, Chicago, IL, USA) statistical software was employed for all analyses. For each animal, every two consecutive tail-flick latencies were averaged before (baseline) and after (post-shock) footshock. Means of these two-point blocks were used in the repeated-measures ANOVA. Baseline and post-shock tail-flick latencies were analyzed separately with drug treatment serving as the between-subjects factor and time serving as the within-subjects factor. Post-injection tail-flick latencies, determined immediately prior to footshock exposure, were averaged into a single determination for each animal and averaged across animals for each drug treatment; this measure was calculated to facilitate statistical comparisons of drug-induced changes in the basal nociceptive threshold observed prior to footshock (post-injection tail-flick.

**Fig. 1.** Dorsal horn neurons express high levels of DGL-α mRNA. (A) In situ hybridization using an antisense riboprobe for DGL-α mRNA. (B) In contrast, staining reaction with the sense probe directed against the complementary mRNA sequence shows no labeling, demonstrating the specificity of the in situ hybridization. (C and D) DGL-α-expressing cells in the dorsal horn of the spinal cord at higher magnification. (Boxed area in A and C is enlarged in D.) Note that DGL-α mRNA levels vary from low to high in distinct cells (D), though no obvious layer-specific pattern is observable in relation to expression levels (C). Scale bars, 100 μm (A and B), 50 μm (C), 10 μm (D).
latency), with baseline tail-flick latencies. In all studies, the Greenhouse-Geisser correction (Greenhouse & Geisser, 1959) was applied to the interaction term of all repeated factors. Post hoc comparisons were evaluated for all main effects using Fisher’s protected least-squares difference (PLSD) to correct for inflated alpha error, with \( P < 0.05 \) considered as statistically significant.

**Fig. 2.** Accumulation of DGL-\( \alpha \) and CB\(_1\) cannabinoid receptor proteins in the dorsal horn of mouse spinal cord. (A and C) Light micrographs of DGL-\( \alpha \) immunoreactivity in the spinal cord using the ‘INT’ antibody. The highest density of immunostaining is located in the superficial layers. In addition, a number of immunopositive cell bodies are visualized in the ventral horn. (B and D) The specificity of the antibody is indicated by the lack of immunostaining in the presence of its blocking peptide (BP). (E and G) Immunostaining for CB\(_1\) receptors in the spinal cord of a wild-type CB\(_1\) +/- mouse reveals the strongest labeling in the dorsal horn. A high density of immunoreactivity is visible in the superficial layers of the spinal dorsal horn and in lamina X, around the central canal, which are the termination zones of somatic and visceral nociceptive axons, respectively. Immunostaining in ventral horn appears to be modest, except for lamina IX. (F and H) The specificity of the antibody is confirmed by the lack of immunostaining in a section from a CB\(_1\)-knockout animal CB\(_1\) \(-/-\). (I and J) At higher magnification, a very dense punctate staining pattern is observed in both (I) the DGL-\( \alpha \) and (J) the CB\(_1\) immunostainings in the superficial layers, indicating the accumulation of these two proteins into selected subcellular compartments. Scale bars, 200 \( \mu \)m (A, B, E and F), 100 \( \mu \)m (C, D, G and H), 20 \( \mu \)m (I and J).

**Fig. 3.** DGL-\( \alpha \) is present in dendritic shafts and spine heads found postsynaptically to primary nociceptive terminals in the mouse superficial dorsal horn. (A, C and D) High-power electron micrographs of DGL-\( \alpha \) immunostaining demonstrate that DGL-\( \alpha \) is located postsynaptically, in the heads of dendritic spines (s) and in dendritic shafts (d) represented by the dense end-product of the immunoperoxidase reaction (DAB; double arrowheads). These DGL-\( \alpha \)-containing spines and shafts receive asymmetrical synapses (arrowheads) from DGL-\( \alpha \)-negative peptidergic nonglomerular boutons (A), type I synaptic glomeruli (C-nociceptive terminal in C) or type II synaptic glomeruli (A\( \delta \)-nociceptive terminal in D). Note (C) the small, indented type I central terminal with dark axoplasm, closely packed spherical vesicles of variable size, lack of mitochondria, and several neuropeptide-containing dense-core vesicles (arrows) and (D) electronlucent, larger type II bouton with regular contour, loosely distributed synaptic vesicles of uniform diameter, numerous mitochondria and axon endings (t) in apposition to the central terminal. (B, E and F) Pre-embedding immunogold staining demonstrates the presence of DGL-\( \alpha \) on the plasma membrane of the head of dendritic spines and shafts. High-power electron micrographs show dendritic shafts (d) and spines (s) situated postsynaptically to small boutons (b in B) and central terminals of (E) type I and (F) type II synaptic glomeruli, corresponding to C- and A\( \delta \)-nociceptive glutamatergic axon terminals, respectively. The gold particles (thin arrows), representing the precise subcellular localization of DGL-\( \alpha \), are always attached to the intracellular surface of the plasma membrane in accordance with the predicted position of the epitopes of DGL-\( \alpha \) protein. Synaptic specializations are labeled with arrowheads while thick arrows depict dense-core vesicles. Scale bars, 0.1 \( \mu \)m.
Results

Distribution of DGL-α enzyme and CB₁ receptor in the spinal cord

To determine the cellular source of 2-AG in the spinal cord, we first examined the expression pattern of DGL-α, its main synthesizing enzyme (Bisogno et al., 2003). Nonradioactive free-floating in situ hybridization on mouse spinal cord sections with an antisense riboprobe revealed widespread DGL-α expression throughout the spinal cord (Fig. 1A and C), whereas no significant labeling was found with the control sense probe (Fig. 1B). Most if not all neurons expressed DGL-α mRNA at variable levels in the dorsal horn (Fig. 1C).
and D), but DGL-α-positive cells were also scattered in the intermediate spinal cord (Fig. 1A). Remarkably, the highest DGL-α mRNA expression in the spinal cord was observed in large cells presumably corresponding to the spinal motoneurons in the ventral horn (Fig. 1A). Importantly, we must note that the in situ hybridization reactions were performed under highly stringent conditions to avoid any nonspecific labeling, which may have resulted in reduced sensitivity. Nevertheless, the widespread distribution of DGL-α mRNA suggests that spinal cord neurons in all spinal laminae express the synthesizing enzyme of 2-AG.

To elucidate the distribution of the DGL-α protein in the spinal cord, immunostainings for DGL-α with a DGL-α ‘INT’ rabbit antibody directed against a 118-residue long internal segment of the enzyme (residues 790–908) and with a C-42 guinea pig antibody raised against the C-terminal tail (residues 1003–1044) were carried out on wild-type mouse and rat spinal cord sections (Fig. 2A–D and I; Supporting information Fig. S1, A). A widespread punctate immunolabeling pattern was found with both antibodies directed against independent epitopes across the entire grey matter, with the highest density located in the dorsal horn of the spinal cord, the central termination zone of primary afferents (Fig. 2A, C and I; supporting Fig. S1, A). Besides the characteristic punctate labeling, scattered cell bodies immunoreactive for DGL-α were also visualized with the staining in the ventral spinal cord (Fig. 2A). When the peptide fragment used as epitope for antibody generation was added to the primary antibody incubation mixture no labeling was found on spinal cord sections (Fig. 2B and D).

Light-microscopic analysis of CB1 immunostaining performed by a highly sensitive antibody (Fukudome et al., 2004) revealed a distribution of the CB1 receptor very similar to that of DGL-α in the mouse and rat dorsal spinal cord (Fig. 2E, G and J; supporting Fig. S1, B). The most profound CB1 immunoreactivity was seen in the superficial layers, where strong accumulation of the receptor protein was represented by very dense puncta at higher magnification (Fig. 2J). Strong staining was also observed in the dorsolateral funiculus, where longitudinal fibers of intrasegmental connections, ascending projections and descending modulatory systems are situated (Fig. 2E and G; supporting Fig. S1, B), and also in lamina X, around the central canal, in a site of termination of visceral afferents (Fig. 2E). Interestingly, a dense CB1 staining was also seen in the ventral horn, in the same area where strong DGL-α immunoreactivity was observed (Fig. 2E and A). The specificity of the antibody was confirmed by the lack of immunolabeling in sections derived from CB1-knockout mice (Fig. 2F and H). Taken together, immunostainings for DGL-α and CB1 provide evidence that the molecular components responsible for mediating 2-AG synthesis and action are present in the spinal cord.
CB₁ receptors are located presynaptically on excitatory axon terminals in the mouse superficial dorsal horn. (A, B, E and F) High-power electron micrographs demonstrate that CB₁ receptors (visualized by DAB precipitate) are present in excitatory axon terminals forming asymmetric synapses (arrowheads) in the mouse dorsal spinal cord. Small boutons (b+ and b, in A and B) and synaptic glomeruli, corresponding to (E) peptidergic C-fiber (dense-core vesicles are indicated by arrows) and (F) Aδ-fiber terminals, show strong CB₁ immunoreactivity. (A) ‘b−’ labels an immunonegative axon ending. (C, D, G and H) Pre-embedding immunogold labeling for CB₁ demonstrates that the receptor (arrow) is located presynaptically on the plasma membrane of small excitatory terminals (b, b₁ and b₂, in C and D) and nociceptive C- or Aδ-boutons (in G and H, respectively). Labels: s, s₁ and s₂, dendritic spines in synaptic connection with small boutons and glomerular terminals; d, dendrite and t, axon terminal surrounding the glomerular terminals. Scale bars, 0.1 μm.
with the highest density in the termination zone of primary nociceptive axons.

**Postsynaptic DGL-α enzyme and presynaptic CB₁ receptor are located at primary nociceptive synapses**

To determine which subcellular compartments underlie the characteristic punctate staining pattern observed at the light microscopic level, we performed a detailed electron microscopic analysis of DGL-α localization in mouse and rat spinal cord sections. Samples for electron microscopy were selected from layers I–III of the dorsal spinal cord to ensure complete primary afferent distribution in the superficial layers. High-magnification electron microscopic analysis demonstrated that the diffusible DAB end-product of the immunoperoxidase staining, which indicates the subcellular localization of DGL-α, was concentrated in a large number of dendritic spine heads (Fig. 3A and C; supporting Fig. S1, C) and also in small diameter dendrites (Fig. 3D; supporting Fig. S1, D). The DGL-α-immunopositive spines and dendrites received asymmetric synapses from DGL-α-negative excitatory axon terminals (Fig. 3A), including boutons belonging to either type I or type II synaptic glomeruli based on their morphological features (Ribeiro-da-Silva & Coimbra, 1982; for detailed ultrastructural criteria see Materials and methods) and corresponding to nerve endings of unmyelinated C-fibers (Fig. 3C; supporting Fig. S1, C) and myelinated Aδ-fibers (Fig. 3D; supporting Fig. S1, D), respectively. In contrast to the high density of DGL-α at asymmetric synapses, the presence of this enzyme at symmetric, putative glycinergic and/or GABAergic synapses could not be unequivocally established. However, we cannot rule out the possibility that DGL-α is also present at
inhibitory synapses at low levels. False-negative results in our immunostainings could be due to several factors such as epitope masking at inhibitory synapses and/or insufficient affinity of the antibodies, and our labeling method for visualizing the enzyme at very low density (Fritschy, 2008).

Silver-intensified immunogold staining also confirmed the subcellular accumulation of DGL-α on spine heads and dendrites situated postsynaptically to small excitatory axon terminals and both types of synaptic glomeruli in the superficial dorsal horn (Fig. 3B, E and F).

In the next set of experiments, we aimed to unravel whether there is an anatomical basis for group I mGluR-induced 2-AG synthesis in the dorsal spinal cord, as previously described in several brain areas (Robbe et al., 2002; Jung et al., 2005, 2007; Lafourcade et al., 2007; Uchigashima et al., 2007; Drew et al., 2008). In colocalization experiments, we performed double immunogold–immunoperoxidase (DAB) immunostainings using anti-DGL-α antibody developed in rabbit and anti-mGluR5 developed in guinea pig. Extensive electron microscopic analysis confirmed that DGL-α was indeed localized on mGluR5-positive dendritic spines receiving asymmetrical synapses from central axon terminals of C- and Aδ-fibers (type I or II synaptic glomeruli, respectively; Fig. 4, A1, A2 and B). These anatomical findings demonstrate that the enzymatic machinery of 2-AG synthesis and its upstream triggering receptor are located around the postsynaptic side of primary nociceptive synapses.

The cellular and ultrastructural localization of CB1 cannabinoid receptors in the spinal cord have been controversial to date (Hohmann & Herkenham, 1998; Farquhar-Smith et al., 2000; Salio et al., 2002; Agarwal et al., 2007). To determine the precise subcellular distribution of 2-AG’s molecular target, we used a highly sensitive second-generation CB1 antibody whose specificity has been confirmed in CB1-knockout animals (Fig. 2E and F; Fukudome et al., 2004). Electron microscopic analysis in the superficial dorsal horn of mouse and rat spinal cords revealed that the diffusible reaction product DAB, indicating the presence of CB1 receptors, was concentrated predominantly in excitatory axon terminals, forming asymmetrical synapses (Fig. 5A and B; supporting Fig. S1, E1, E2 and F). Moreover, presynaptic CB1 immunolabeling was also found, albeit at a low level, in axon endings that can be identified by morphological criteria as forming type I or type II synaptic glomeruli (Ribeiro-da-Silva & Coimbra, 1982; Fig. 5E and F; supporting Fig. S1, F and G). In accordance, immunogold staining also confirmed presynaptic CB1 receptors on small boutons (Fig. 5C and D) and on primary nociceptive axon terminals (Fig. 5G and H), both forming asymmetrical synapses on their postsynaptic targets. Gold particles, indicating the precise subcellular position of CB1, were always attached to the presynaptic plasma membrane, often adjacent to the active zone (Fig. 5C, G and H).
Retrograde 2-AG signaling mediates mGluR5-dependent analgesia in vivo

The above anatomical findings indicate that the molecular machinery initiating retrograde 2-AG signaling is present at nociceptive synapses. Thus, in subsequent experiments, we examined functional evidence for the involvement of this molecular machinery in endocannabinoid-mediated stress-induced analgesia (SIA), a behavioral phenomenon in which animals are less responsive to noxious stimulation following exposure to an environmental stressor. This animal model of stress-induced analgesia (Hohmann et al., 2005) has been shown to mobilize 2-AG, but not anandamide, in the lumbar spinal cord (Suplita et al., 2006). Baseline tail-flick latencies, measured prior to drug or vehicle administration, did not differ between groups, with one exception. In each study, vehicle alone had no effect on the basal nociceptive threshold, assessed relative to baseline tail-flick latencies. Moreover, none of the drugs, some of which were specifically employed at low doses, altered the basal nociceptive threshold; post-injection tail-flick latencies, assessed prior to footshock, did not differ between groups in any study. Thus, the pharmacological manipulations employed here specifically altered tail-flick latencies in a state-dependent fashion that was apparent under conditions in which the endocannabinoid system was specifically activated during stress antinociception. In all studies, exposure to footshock stress produced antinociception, as revealed by the observation of time-dependent changes in post-shock tail-flick latencies (main effect of post-shock time, \(P < 0.0001\)).

Intrathecal administration of the group I mGluR agonist DHPG (0.02 or 0.2 \(\mu g\)) induced a time-dependent enhancement of post-shock tail-flick latencies relative to vehicle controls (interaction between DHPG and post-shock time, \(F_{1,18,225} = 2.14, P = 0.02;\) Fig. 6A). The mGluR3 antagonist MPEP strongly suppressed the antinociceptive effect produced by footshock (main effect of MPEP, \(F_{3,30} = 3.52, P = 0.03;\) Fig. 6B) and altered the time course of stress antinociception (interaction between MPEP and post-shock time, \(F_{2,27,270} = 4.63, P < 0.0001;\) Fig. 6B). *Post hoc* analysis revealed that the high (0.23 \(\mu g\) i.t.) and middle (2.3 \(\times 10^{-4} \mu g\) i.t.) doses of MPEP suppressed stress antinociception relative to the low (2.3 \(\times 10^{-5} \mu g\) i.t.) dose (\(P = 0.01\) and 0.049, respectively). The high dose of MPEP also suppressed stress antinociception relative to vehicle (\(P = 0.02\)). The low dose of MPEP was insufficient to alter stress antinociception (\(P = 0.70\)). This same dose of MPEP nonetheless blocked the time-dependent enhancement of stress antinociception induced by DHPG (0.2 \(\mu g\) i.t.; interaction between drug treatment and post-shock time, \(F_{1,18,207} = 2.81, P = 0.006;\) Fig. 6C). Stress antinociception was greater in groups receiving DHPG (0.2 \(\mu g\) i.t.) alone compared to DHPG co-administered with MPEP (main effect of treatment, \(F_{1,14} = 4.79, P = 0.046\)). By contrast, stress antinociception was similar in groups receiving vehicle and groups receiving DHPG co-administered with MPEP (\(F_{1,16} = 0.003, P = 0.96\)). The CB1 antagonist rimonabant (10 \(\mu g\) i.t.) also blocked the time-dependent enhancement of stress antinociception induced by DHPG (interaction between drug treatment and post-shock time, \(F_{1,18,225} = 2.29, P = 0.03;\) Fig. 6D). Stress antinociception was greater in groups receiving DHPG (0.2 \(\mu g\) i.t.) alone than DHPG co-administered with rimonabant over 25 min post-shock (interaction between drug treatment and post-shock time, \(F_{6,84} = 2.92, P = 0.04;\) Fig. 6D). By contrast, stress antinociception was similar in groups receiving either vehicle or DHPG co-administered with rimonabant over the same interval (\(F_{6,109} = 1.52, P = 0.20\)). THL, the most potent pharmacological inhibitor of DGL (Bisogno et al., 2003, 2006) presently available, also suppressed stress antinociception relative to vehicle controls (main effect of THL, \(F_{2,27} = 4.43, P = 0.02;\) Fig. 7A). Both the high (100 \(\mu g\) i.t.; \(P = 0.02\)) and middle (10 \(\mu g\) i.t.; \(P = 0.04\)) doses of THL similarly suppressed post-shock tail-flick latencies relative to vehicle. The low dose of THL (1 \(\mu g\) i.t.) was insufficient to alter post-shock tail-flick latencies (\(F_{1,12} = 0.64, P = 0.44;\) Fig. 7B) but, nonetheless, blocked the DHPG-induced enhancement of stress antinociception (interaction between drug treatment and post-shock time, \(F_{1,18,189} = 9.40, P < 0.0001;\) Fig. 7C). Stress antinociception was greater (main effect of drug treatment, \(F_{2,21} = 15.07, P < 0.0001;\) Fig. 7C) in groups receiving DHPG (0.2 \(\mu g\) i.t.) than those receiving either DHPG (0.2 \(\mu g\) i.t.) co-administered with THL (1 \(\mu g\) i.t.) or vehicle (\(P < 0.0001\) for each comparison). Co-administration of DHPG together with THL did not alter stress antinociception relative to vehicle (\(P = 0.91;\) Fig. 7C). Taken together, these data show that the mGluR3-DGL-z-CB1 pathway mediates stress-induced analgesia.

Discussion

Various experimental approaches have been applied to the characterization of the antinociceptive effects of exogenous cannabinoids in acute and persistent pain states (for review, see Walker & Hohmann, 2005). However, the molecular architecture of endogenous cannabinoid signaling involved in the physiological regulation of pain transmission has remained largely unknown. Here, we have provided anatomical evidence that mGluR3 and DGL-z, the first and last molecular components in the biosynthetic pathway of the endocannabinoid 2-AG, are concentrated on the postsynaptic side of primary nociceptive synapses, while its effector, the CB1 cannabinoid receptor, is concentrated presynaptically. Furthermore, we have shown that these molecular players are functionally linked together in the production of endocannabinoid-mediated stress-induced analgesia *in vivo*. These findings suggest that nociceptive synapses are equipped with an intrinsic feedback system, the retrograde 2-AG signaling pathway, which regulates nociception in an activity-dependent manner.

Molecular components of retrograde 2-AG signaling are present at central synapses of primary nociceptive afferents

The dorsal spinal cord has a pivotal role in nociceptive sensory information processing. Neurons in laminae I–III of Rexed receive most inputs from unmyelinated polymodal C-fibers and thinly myelinated mechanoreceptor A\(\delta\)-fibers of primary afferents (for review, see Milán, 1999), the vast majority of which (~90% of C-fibers and 70% of A\(\delta\)-fibers) carry nociceptive information (Fang et al., 2005). A remarkable morphological feature of these afferents, classified physiologically on the basis of their conduction velocities, is their characteristic central axon terminal surrounded by other synaptic profiles, forming the so-called synaptic glomeruli (Rëthelyi et al., 1982; Ribeiro-da-Silva & Coimbra, 1982). Using specific morphological criteria of synaptic glomeruli (Ribeiro-da-Silva & Coimbra, 1982; Ribeiro-da-Silva, 1995; see also Materials and methods for details), we identified primary afferent terminals in the spinal dorsal horn and demonstrated the presence of molecular players of 2-AG synthesis and action at excitatory synapses formed by C- and A\(\delta\)-fibers. Cellular and subcellular sources of endocannabinoids have not previously been identified in the spinal cord. Our results show that DGL-z is accumulated in the superficial dorsal horn and located postsynaptically to primary afferents, providing a neuroanatomical basis for retrograde 2-AG signaling upon activation of primary nociceptors. DGL-z and its upstream activator, the group I...
metabotropic glutamate receptor mGluR5, whose activation triggers 2-AG synthesis (Jung et al., 2005), are both concentrated perisynaptically on dendritic spines at central glutamatergic synapses (Lujan et al., 1996; Katona et al., 2006). This precise colocalization suggests that these proteins are functionally coupled at these synapses in the so-called perisynaptic signaling machinery to detect excessive glutamate release and produce ‘on demand’ retrograde 2-AG signaling (Katona & Freund, 2008). In the spinal cord, ultrastructural analysis has demonstrated that mGluR5 occurs postsynaptically to excitatory axon terminals, and it is located in dendrites receiving synapses from primary afferent Aβ- and C-glomerular fiber endings (Alvarez et al., 2000; Tao et al., 2000; Pitcher et al., 2007). Here, we have provided evidence for colocalization of DGL-α and mGluR2 in postsynaptic compartments apposing these terminals. This demonstration proves that the molecular machinery for mGluR3-induced 2-AG synthesis, as previously described in the brain (Lafourcade et al., 2007; Uchigashima et al., 2007), is also present on the postsynaptic side of nociceptive synapses formed by incoming primary afferents.

Our high-resolution anatomical analysis demonstrated that CB1 receptors, the molecular targets of 2-AG, are located presynaptically, on small excitatory axon terminals and on primary afferent fiber endings. Several studies have reported widespread CB1 distribution in the spinal cord (Hohmann & Herkenham, 1998; Hohmann et al., 1999; Farquhar-Smith et al., 2000; Salio et al., 2002), and PKCθ-immunoreactive excitatory interneurons have been proposed as the predominant CB1-positive cell type in the dorsal horn (Farquhar-Smith et al., 2000). However, the presence of CB1 on central primary afferent terminals has remained ambiguous because of modest CB1 colocalization with primary afferent markers and a minor reduction in CB1 immunoreactivity after dorsal rhizotomy (Farquhar-Smith et al., 2000; Price et al., 2003; see also Ahluwalia et al., 2000; Mitirattanakul et al., 2006; Agarwal et al., 2007). Low antibody sensitivity may have contributed to this interpretation, because the high affinity cannabinoid agonist [3H]CP55,940 binding demonstrated using quantitative autoradiography was reduced by ~50% after extensive unilateral dorsal rhizotomy (Hohmann et al., 1999). Importantly, novel, highly sensitive second-generation CB1 antibodies that are able to detect CB1 receptors on hippocampal glutamatergic axons (Katona et al., 2006; Kawamura et al., 2006), in which CB1 protein levels are below the detection threshold for antibodies previously used in spinal cord studies (Katona et al., 1999; Egertova & Elphick, 2000; Farquhar-Smith et al., 2000; Salio et al., 2002), were employed here. Use of this second-generation antibody has enabled us to directly demonstrate the presence of CB1, albeit at low levels, on central terminals of primary nociceptive C- and Aδ-fibers. CB1 activation also inhibits C-fiber- and A-fiber-evoked neuronal responses of dorsal horn neurons (Chapman, 1999; Strangman & Walker, 1999; Drew et al., 2000; Kelly & Chapman, 2001; Morisset & Urban, 2001). The physiological and anatomical findings together suggest that 2-AG, released from dendritic processes situated postsynaptically to primary afferent terminals, can target presynaptic CB1 receptors, located either on nociceptive fibers or on local excitatory interneurons, thereby leading to inhibition of nociceptive excitatory transmission.

Spinal 2-AG signaling is involved in group I mGluR-dependent stress-induced analgesia in vivo

In our behavioral experiments, we aimed to determine what functional roles the molecular components of 2-AG signaling, described at primary nociceptive synapses, may play in pain sensation in vivo, using an animal model of endocannabinoid-mediated stress-induced analgesia (SIA). Group I mGluRs have previously been implicated in modulating exogenous cannabinoid antinociception (Palazzo et al., 2001). Here we have shown that activation of mGluR5 enhances endogenous cannabinoid-mediated stress antinociception under physiological conditions, in a manner dependent upon DGL and CB1 receptor activation. These results are in accordance with in vitro and in vivo electrophysiological, biochemical and anatomical studies suggesting a functional link between mGluR5 and endocannabinoid signaling (Maejima et al., 2001; Robbe et al., 2002; de Novellis et al., 2005; Lafourcade et al., 2007; Drew et al., 2008) in the brain.

Exposure to the footshock stressor used here to induce stress antinociception elevates 2-AG, but not anandamide, levels in the lumbar spinal cord (Suplita et al., 2006). Moreover, stress antinociception correlates highly with 2-AG mobilization in the lumbar spinal cord (Suplita et al., 2006) and cannot be attributed to motor suppression (Suplita et al., 2008). The involvement of 2-AG in stress-antinociception at the spinal level is further supported by the observation that i.t. inhibition of monoacylglycerol lipase, the major degrading enzyme of 2-AG (Dinh et al., 2002; Blankman et al., 2007), produces a profound CB1-mediated enhancement of SIA (Suplita et al., 2006). These findings are consistent with the in vitro results documenting that mGluR5 activation induces 2-AG release (Jung et al., 2005, 2007; Lafourcade et al., 2007; Uchigashima et al., 2007; Drew et al., 2008) but does not alter anandamide levels in brain slice cultures (Jung et al., 2005). The observations that postsynaptic group I mGluRs activate phospholipase Cβ (PLCβ; Pin & Duvoisin, 1995) and that 2-AG biosynthesis is initiated by activation of the PLCβ–DGL pathway in vitro (Bisogno et al., 2003; Jung et al., 2005, 2007; Hashimotodani et al., 2008) suggest that mGluR5 activation induces PLCβ-mediated diacylglycerol production which serves as a precursor for DGL-α-mediated 2-AG synthesis. Indeed, pharmacological inhibition of DGL at the spinal level with i.t. THL suppressed endocannabinoid-mediated SIA in our study. The enhancement of stress antinociception induced by group I mGluR activation with DHPG was also blocked by a pharmacological inhibitor of DGL. Thus, DHPG enhanced stress antinociception only under conditions in which 2-AG is mobilized at the spinal level to produce endocannabinoid-mediated SIA (Suplita et al., 2006). We have previously demonstrated that spinal antagonism of CB1 per se did not alter the phenomenon of footshock-induced nonopioid SIA, although spinal 2-AG levels were nonetheless selectively increased by the same footshock stressor and correlated highly with SIA (Suplita et al., 2006). On the other hand, here we provide evidence that enhancement of SIA by group I mGluR activation requires activation of CB1 as a necessary, but not sufficient, prerequisite at the spinal level. Because the CB1 antagonist rimonabant microinjected into the dorsolateral PAG at the same dose strongly suppressed stress-antinociception per se (Hohmann et al., 2005), this discrepancy suggests that the molecular signaling cascade described above operates with a lower induction threshold in the PAG than in the spinal cord. Whether higher midbrain density of group I mGluRs, PLCβ, DGL-α or CB1 (or all) underlies the enhanced sensitivity and the more pronounced involvement of PAG in SIA is an interesting question to examine in future experiments. In any case, our studies collectively suggest that activation of group I mGluRs enhances endocannabinoid-mediated stress antinociception through the mGluR5–DGL–2-AG pathway via CB1 receptor activation at the spinal level. Previous behavioral studies indicated that, in several models of acute or chronic pain, pharmacological stimulation of group I
mGluRs by i.t. application of high doses of DHPG had nociceptive effects (Fisher & Codere, 1996a, b, 1998; Karim et al., 2001; Adwanikar et al., 2004; Gabra et al., 2007). Conversely, specific blockade of mGluR5 by MPEP applied at high concentrations induced analgesia (Karim et al., 2001; Walker et al., 2001; Fisher et al., 2002) and blocked neuronal activity in the dorsal horn induced by noxious stimulation (Fisher & Codere, 1996a). These observations are generally in accordance with the dendritic localization of postsynaptic mGluR5 responding to glutamatergic nociceptive primary afferents, implying the involvement of mGluR5 in the spinal processing of nociceptive information. However, in the present experiments, DHPG and MPEP were used at ten times lower concentrations; these did not alter basal nociceptive thresholds in the tail-flick test per se and enhanced or reduced stress-induced analgesia, respectively, under conditions in which 2-AG is specifically mobilized at the spinal level. This dose difference suggests that activation of group I mGluRs may first have an antinociceptive effect by evoking 2-AG synthesis and release in given pain paradigms, whereas a higher ratio of glutamatergic activation of nociceptive neurons may lead to the initiation of other, predominantly pro-nociceptive, signaling cascades.

In the paradigm of nonopioid stress-induced analgesia (Hohmann et al., 2005) used in our experiments, the delivery of a 3-min continuous electric footshock is followed by the reduction of pain sensation measured by tail-flick latency, resulting in intersegmentally mediated endocannabinoid-dependent stress antinociception. A possible scenario is that primary afferent terminals of the hindleg, located in lumbar spinal segments (L2-L6; Swett & Woolf, 1985), releasing excessive glutamate following footshock, may trigger mGluR5-DGL-α-mediated 2-AG production in second-order neurons. Interneurons located in the area of tail afferent nociceptor terminals (S3-Co3; Grossman et al., 1982), and making propriospinal connections linking these nociceptors to tail-flick motoneurons in L4-Co2 segments (Grossman et al., 1982), might impinge on 2-AG-releasing interneurons. Thus, 2-AG may mediate homo- and/or heterosynaptic inhibition of nociception acting on presynaptic CB1 located on hindleg afferent terminals and intersegmental interneuron axon endings, respectively. Both scenarios are supported by our electron microscopic observations.

Group I mGluR activation is involved in various forms of homo- and heterosynaptic plasticity (for review, see Bellone et al., 2008), including induction of long-term depression (LTD) of synaptic transmission between αδ-fibers and second-order neurons (Heinke & Sandkühler, 2005). Thus, a possible physiological mechanism of inhibition of spinal pain processing may be an mGluR5-dependent, endocannabinoid-mediated short-term suppression or LTD of synaptic transmission, already described in the brain (Robbe et al., 2002; Chevalleyre & Castillo, 2003; Uchigashima et al., 2007).

The present study focused on understanding neuronal 2-AG signaling, because glial expression levels of DGL-α in naive animals remained below the detection threshold of our methods. However, in the spinal cord, potential non-neuronal sources of endocannabinoids should also be considered, particularly under conditions of injury or other pathological challenge. In experiments using cell cultures, glial cells such as astrocytes and microglia express mGluRs receptors (Biber et al., 1999) and possess the capacity for 2-AG synthesis and release (Walter & Stella, 2003; Carrier et al., 2004; Walter et al., 2004; Witting et al., 2004). At the supraspinal level, microglial cells are activated after footshock (Blandino et al., 2006), suggesting that activated glial cells could also potentially participate in spinal 2-AG signaling. Further studies are thus needed to assess the relative contribution of glial endocannabinoids to antinociception in different pain paradigms.

Taken together, our findings in the spinal cord are consistent with a common molecular architecture responsible for retrograde 2-AG signaling throughout the brain, in which 2-AG may be a key negative feedback signal at many central synapses (Kataoka & Freund, 2008). Based on the findings reported here, we propose that this retrograde signaling pathway also controls nociceptive responding in vivo by suppressing pain transmission at the spinal level in an activity-dependent manner.

Supporting Information

Additional supporting information may be found in the online version of this article:

Fig. S1. DGL-α and CB1 cannabinoid receptors are present on opposite sides of primary nociceptive synapses in the rat dorsal spinal cord. Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

Acknowledgements

This work was supported by Hungarian Health Science Council (E.T.T.) Grant 561/2006 and the János Bolyai scholarship (I.K.), and by National Institutes of Health Grants DA021644, DA022478 and DA022702 (A.G.H.), DA11322 and DA121696 (K.M.). The authors are grateful to Dr Anke Tappe-Theodore and Gabriella M. Urbán for their valuable contribution to preliminary experiments, to Barna Dudok and Dr Mark D. Eyre for help with confocal microscopic analysis and to Professor Tamás F. Freund for supporting this project. We also thank Professors Rohini Kuner, Hanns Ulrich Zeilhofer and Miklós Réthelyi for discussion and Dr Viktor Varga for comments on the manuscript, and John Calhoun, Katalin Lengyel, Katalin Iványi, Emőke Szépén Simon and Gyöző Goda for excellent technical assistance.

Abbreviations

2-AG, 2-arachidonoylglycerol; C-42, polynonal guinea pig anti-DGL-α antibody directed against the C-terminal tail of the enzyme; CB1, type 1 cannabinoid receptor; DAB, 3,3-diaminobenzidine; DGL-α, diacylglycerol lipase-alpha; DHPG, (S)-3,5-dihydroxyphenylglycine; Fischer’s PLSD, Fisher’s protected least-squares difference; i.t., intrathecal or intrathecally; INT, internal segment of the enzyme; mGluR, metabotropic glutamate receptor; MPEP, 2-methyl-6-(phenylethynyl)pyridine; PB, phosphate buffer; SIA, stress-induced analgesia; THL, N-formyl-l-leucine (1S)-1-[[25,3S]-3-hexyl-4-oxo-2-oxetanylmethyl]dodecyl ester [also known as (−)-tetrahydrolipstatin].

The studies described in this paper were supported by National Institutes of Health Grants DA021644, DA022478 and DA022702 (A.G.H.), DA11322 and DA121696 (K.M.). The authors are grateful to Dr Anke Tappe-Theodore and Gabriella M. Urbán for their valuable contribution to preliminary experiments, to Barna Dudok and Dr Mark D. Eyre for help with confocal microscopic analysis and to Professor Tamás F. Freund for supporting this project. We also thank Professors Rohini Kuner, Hanns Ulrich Zeilhofer and Miklós Réthelyi for discussion and Dr Viktor Varga for comments on the manuscript, and John Calhoun, Katalin Lengyel, Katalin Iványi, Emőke Szépén Simon and Gyöző Goda for excellent technical assistance.


© The Authors (2009). Journal Compilation © Federation of European Neuroscience Societies and Blackwell Publishing Ltd

European Journal of Neuroscience, 29, 1964–1978
Antinociceptive 2-AG signaling in the spinal cord 1977


